Related Experiment Videos
NIDDK-sponsored chronic prostatitis collaborative research network (CPCRN) 5-year data and treatment guidelines for
1Department of Urology, Feinberg School of Medicine, Northwestern University, Tarry 11-715, Chicago, IL 60611, USA. ajschaeffer@northwestern.edu
International Journal of Antimicrobial Agents
|September 15, 2004
Summary
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) significantly impacts patients. Research suggests anti-inflammatory and alpha-blocker therapies show promise for managing CP/CPPS symptoms.
Area of Science:
- Urology
- Pain Management
- Clinical Research
Background:
- Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a poorly understood and disabling condition.
- Significant research efforts are underway to understand and manage CP/CPPS.
- The condition has a substantial impact on patients' lives.
Framework:
- A multi-faceted research approach was employed, including a symptom index, cohort study, case-control study, and randomized clinical trials.
- Basic science research was integrated with clinical studies.
- Resource utilization studies were conducted to assess the condition's impact.
Implementation:
- A collaborative research network was established.
- Multiple study designs were utilized to gather comprehensive data.
- Patient cohorts were formed for in-depth analysis.
Implications:
- Anti-inflammatory and alpha-blocker therapies show potential effectiveness for CP/CPPS.
- Oral fluoroquinolone therapy remains effective for a subset of patients with bacterial prostatitis.
- Further research is crucial for improved CP/CPPS management strategies.